CD38
- Known as:
- CD38
- Catalog number:
- 1T-366-T025
- Product Quantity:
- 25 tests
- Category:
- -
- Supplier:
- Exbio
- Gene target:
- CD38
Related genes to: CD38
- Gene:
- CD38 NIH gene
- Name:
- CD38 molecule
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 4p15.32
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2014-11-18
Related products to: CD38
Related articles to: CD38
- The coexistence of antibody-mediated rejection (AMR) and BK polyomavirus-associated nephropathy (BKPyVAN) represents a major therapeutic challenge after kidney transplantation. Whereas treatment of AMR typically requires intensification of immunosuppression, management of BKPyVAN relies on reduction of immunosuppressive therapy to restore antiviral immune control. We report a kidney transplant recipient who developed active AMR with de novo donor-specific antibodies and concurrent BKPyVAN 12 weeks after transplantation. Given ongoing BKPyV replication, recent infectious complications, and concerns regarding further escalation of conventional immunosuppressive therapy, the patient was treated with pulse methylprednisolone followed by anti-CD38 therapy using daratumumab. Treatment resulted in recovery of allograft function, disappearance of donor-specific antibodies, and complete histological resolution of AMR. BKPyV replication subsequently declined and ultimately resolved without recurrent rejection. This case highlights CD38 blockade as a potential therapeutic option in selected patients with concomitant AMR and BKPyVAN. However, given the concurrent administration of corticosteroids and optimization of maintenance immunosuppression, these findings should be regarded as hypothesis-generating. - Source: PubMed
Publication date: 2026/10/02
Traub ShuyangMenter ThomasSchaub StefanDiebold Matthias - Plasma cell neoplasms (PCNs) are a group of malignant neoplasms originating from the monoclonal expansion of immunoglobulin-secreting, terminally differentiated B cells, i.e., plasma cells (PCs). PCNs include monoclonal gammopathy of undetermined significance (MGUS), plasmacytoma (solitary plasmacytoma of the bone and extramedullary plasmacytoma), multiple myeloma (MM)/plasma cell myeloma, and rare PCNs associated with paraneoplastic syndromes. MM is a multifocal, bone marrow-based clonal PCN associated with end-organ damage and a monoclonal paraprotein (M protein) in the serum and/or urine. Morphologically, MMs are typically composed of mature to atypical PCs with a typical immunophenotype (CD38 + bright, CD138 + , CD19-, and monotypic light-chain expression), which are usually diagnostically straightforward. However, rare cases with morphological variants or immunophenotypic aberrancies may pose diagnostic challenges. Small, mature-appearing PC variants of MM at times may be difficult to differentiate from mature B-cell lymphomas with plasmacytic differentiation, such as lymphoplasmacytic lymphoma and marginal zone lymphoma, particularly in core needle biopsies. CD20 + and cyclin D1 + MM may mimic mantle cell lymphoma. Plasmablastic and pleomorphic/anaplastic variants are prone to present as extramedullary lesions mimicking plasmablastic lymphoma (PBL) or various types of lymphomas with pleomorphic/anaplastic morphology. Moreover, neoplastic PCs may exhibit aberrant expression of CD3, CD4, CD117, and cyclin D1, leading to potential diagnostic pitfalls. Diffuse CD30 expression with anaplastic morphology may be mistaken for anaplastic large-cell lymphoma. In rare instances, the neoplastic cells of PCNs are positive for Epstein-Barr virus (EBV), more frequently in cases with plasmablastic morphology and extramedullary involvement, which may raise suspicion for PBL. In this review, we emphasize the rare morphological and immunophenotypic features and variants of PCNs and utilize a few examples to highlight the diagnostic challenges. - Source: PubMed
Publication date: 2026/10/02
Chuang Shih-SungChang Chung-Che - Common variable immunodeficiency disease (CVID) is the most prevalent symptomatic inborn errors of immunity, determined by defective B cell function, impaired antibody production, and susceptibility to frequent respiratory infections, enteropathy, autoimmunity, and malignancy. Due to the importance of autoimmunity in CVID and the probable role of regulatory B lymphocytes, we aimed to determine the frequency of B10 cells in CVID patients with and without autoimmunity. A total of 24 CVID patients and 12 healthy controls were enrolled in the study. Patients were divided into two equal groups, with and without autoimmunity. Peripheral blood cells were stained with monoclonal antibodies (mAbs) to identify CD24hiCD38hi B cells, CD27int CD38+ (plasmablasts), and CD24hiCD27+ B cells by flow cytometry. The percentages of B10, CD24hiCD27+ and CD27int CD38+ cells were significantly lower in total CVID patients, CVID patients with autoimmunity and CVID patients without autoimmunity compared to healthy controls (mean±standard deviation (SD) percentage of B10 cells: 6.36±9.21(total CVID), 2.81±5.00 (CVID with autoimmunity), and 3.25±3.5 (CVID without autoimmunity) vs. 13.02±12.45 (healthy controls); CD24hiCD27+ cells: 2.39±3.89, 3±5.20 and 1.78±1.94 vs. 20.38±14.27; CD27int CD38+ cells: 6.80±18.49, 7.40±20.24 and 6.20±17.45 vs. 11.84±5.71). CVID patients without autoimmunity had a higher percentage of CD24hiCD38hi cells than CVID patients with autoimmunity (4.73±4.14 vs. 2.62±5.02). The defect of regulatory B cells plays a significant role in the pathogenesis of autoimmunity in CVID. Further multicenter studies with higher sample sizes are suggested to determine the role of Breg cells in the clinical course of autoimmunity. - Source: PubMed
Publication date: 2026/08/12
Ghiaee PouriaEbrahimi SarehsadatMahdaviani Seyed AlirezaTarighat Monfared FatemehTavakol MarziehDargahi Mal-Amir MehrdadRezaei NimaJafarzadeh Abdollah - Renal impairment is a frequent and adverse prognostic factor in multiple myeloma (MM), with dialysis-dependent patients largely excluded from pivotal trials of B-cell maturation antigen (BCMA)-directed therapies. Elranatamab, a BCMA×CD3 bispecific antibody, has demonstrated significant efficacy in relapsed/refractory multiple myeloma (RRMM); however, data in end-stage renal disease are extremely limited. We report real-world outcomes of four dialysis-dependent RRMM patients treated with elranatamab. - Source: PubMed
Publication date: 2026/09/28
Batgi HikmettullahDilan Köseoğlu FatoşÇetin DenisBaşcı SemihNamdaroğlu SinemAkad Soyer Nur - Complement-dependent cytotoxicity (CDC) of CD38 monoclonal antibodies has been associated with infusion-related reactions and might contribute to reduced clinical efficacy of CDC-reliant CD38 antibodies, particularly in patients with relapsed or refractory multiple myeloma with 1q21+. We aimed to evaluate felzartamab, a novel anti-CD38 monoclonal antibody that retains potent antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis while exhibiting markedly attenuated CDC activity in Chinese patients with relapsed or refractory multiple myeloma. - Source: PubMed
He HaiyanShang JingjingWang YafeiXia ZhongjunZhu FangbingYang YanliFang BaijunChen WenmingChen BingCai ZhenZhou HuiLi YajunLiu HongChen LijuanLiu YanHuang ZhongxiaZeng PengyunJin JieLi YanMi JianqingZhou ZepingGao SujunXi YamingWang QingmingChang ChunkangDu XinHuang Shang-YiWang Hao-YuanKo Po-ShenShao ZonghongLuo JunWang ShunqingHuang JinwenDai MingshenYang TonghuaZhan RongLiang BinWang Ming-ChungWu SuijingZhong LiyeWei YongqiangWang HongxiangWu HuijingLi JuanTeng Chieh-LinMeng YuanWu MinfangYang PingChen XiZhu Andrew XFu WeijunWu DepeiFu Chengcheng